Small Molecules

Richard Stedman from ACG Engineering outlines the trends driving change in the Indian pharmaceutical equipment industry.

Is continuous manufacturing worth the investment for pharma companies?

How can small molecule "degraders" help target disease-causing proteins?

New method to control polymorphism could see “widespread use across the pharma industry”.

Can a medieval medicament find use as a modern antibacterial?

How are counterfeiters exploiting the COVID-19 pandemic to make a profit?

It is essential that drug development incorporates the patient view.

There are ample opportunities for pharma companies to transition to greener chemical processes. Martin Hayes from Johnson Matthey tells us more.

How is the business of making medicine changing in light of the COVID-19 pandemic?

We need to optimize and then accelerate HPAPI drug product development. Alyn McNaughton from Lonza tells us more.